New drug BL-B01D1 tested in patients with advanced cancers

NCT ID NCT05262491

First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 33 times

Summary

This early-phase study tests a new drug called BL-B01D1 in people with advanced stomach or other solid tumors that have not responded to standard treatments. The main goals are to find a safe dose and check for side effects. About 96 adults will take part to see if the drug can help control the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GASTROINTESTINAL TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Cancer Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100037, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Jinan Central Hospital

    RECRUITING

    Jinan, Shandong, China

    Contact

    Contact

    Contact

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, China

    Contact

  • Tianjin Medical University General Hospital

    RECRUITING

    Tianjin, Tianjin Municipality, China

    Contact

  • West China Hospital, Sichuan University

    RECRUITING

    Chengdu, Sichuan, China

    Contact

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, China

    Contact

Conditions

Explore the condition pages connected to this study.